You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Preclinical development of novel small molecule malaria drugs that overcome drug
SBC: DESIGNMEDIX, INC. Topic: NIAIDDESCRIPTION provided by applicant The worldwide health problem created by malaria has been made more difficult by the spread of drug resistant parasites We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine resistant and chloroquine sensitive malaria This project carries on preclinical development of a drug candidate that has been select ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
CG-GRID: Computational Genetics Grid Resource for Interaction Discovery
SBC: PARABON COMPUTATION, INC. Topic: 400DESCRIPTION provided by applicant Advances in DNA sequencing technology have now made it practical and affordable to generate datasets containing millions of genetic attributes that can be tested for association with disease susceptibility The computational complexity of searching for genetic interactions over such high dimensional datasets imposes great challenges for genome wide associatio ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety
SBC: VIRTUALLY BETTER INC Topic: NIMHDESCRIPTION provided by applicant Anxiety disorders are the most common psychiatric disorders among youth with lifetime prevalence ranging between of the general population Among anxiety disorders social anxiety disorder SAD affects of all youth resulting in significant short and long term impairment including increased likelihood of substance abuse limited academic achievemen ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Human monoclonal antibodies for prevention of S. aureus infections
SBC: SORRENTO THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION provided by applicant Using mouse monoclonal antibodies mAbs raised against the mediators of quorum sensing QS the Auto Inducing Peptides AIPs researchers at The Scripps Research Institute TSRI have demonstrated that S aureus infections can be prevented in animal challenge models This approach known as quorum quenching QQ is unique in at least two significant ways fi ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Antigen Detection assay for the Diagnosis of Melioidosis
SBC: Inbios International Inc Topic: NIAIDDESCRIPTION provided by applicant Burkholderia pseudomallei is a Gram negative bacterium that is the causative agent of melioidosis The bacterium causes significant morbidity and mortality in tropical regions and endemic areas are expanding Melioidosis is difficult to trea and diagnose due to the fact that B pseudomallei is resistant to common antibiotics and symptoms are non specific Morta ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
SBC: Immunext, Inc. Topic: NIAIDDESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a devastating autoimmune disease that most commonly affects women in their child bearing years SLE attacks multiple organ systems but renal and neurologic involvement are the usual harbingers of poor outcome Despite effective albeit toxic immunosuppressive therapy only of patients with these serious manifestations ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Targeting B-cell lymphoma with Leukothera-phase II
SBC: Actinobac Biomed, Inc. Topic: NCIDESCRIPTION provided by applicant B cell lymphoma is cancer of B lymphocytes and accounts for more than deaths in the U S each year While many patients respond to currently available therapy there is a high rate of cancer relapse and inability for the patients o tolerate chemotherapy Thus there is a significant need to make available to these patients newer therapies that are more e ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
ECG Device for LQTS Screening in Newborns, Phase II
SBC: QT Medical, Inc. Topic: NHLBIDESCRIPTION provided by applicant The congenital long QT syndrome LQTS is thought to occur in in infants and cause of deaths from SIDS sudden infant death syndrome Electrocardiograms ECGs can detect LQTS before fatal cardiac events happen In our Phase I STTR project we successfully developed and tested an ECG device designed for LQTS screening in newborns This device n ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis
SBC: OASIS PHARMACEUTICALS, LLC Topic: NIDDKDESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p
SBC: AGILE SCIENCES, INC. Topic: NIAIDDESCRIPTION provided by applicant The leading cause of mortality in patients with cystic fibrosis CF is pulmonary failure from lung infections and the predominant organism isolated from these infections is the bacterium Pseudomonas aeruginosa Lung infections of CF patients persist over the lifetime of the patients and are impossible to eradicate due to the ability of bacteria to form biofi ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health